NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Tardive Dyskinesia
Interventions
DRUG

NBI-98854

12.5 mg powder in bottle once daily for 14 days

DRUG

NBI-98854

50 mg powder in bottle once daily for 14 days

DRUG

Placebo

Solution containing no active substance

Trial Locations (11)

25304

CAMC Clinical Trials Center, Charleston

30308

Atlanta Center for Medical Research, Atlanta

33015

San Marcus Research Clinic, Inc., Miami

33155

Medical Research Marseilles, Miami

33161

Scientific Clinical Research, Inc., North Miami

63118

St. Louis Clinical Trials, St Louis

72211

Woodland International Research Group, Inc, Little Rock

78229

Clinical Trials of Texas, Inc., San Antonio

91950

Synergy Clinical Research, National City

92103

UCSD Outpatient Psychiatry, San Diego

92108

PCSD - Feighner Research, San Diego

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY